Compounded tirzepatide is a customized medication prepared by a compounding pharmacy rather than manufactured as an FDA-approved, commercially available product. Tirzepatide is the active drug used in FDA-approved medicines such as Mounjaro and Zepbound, but a compounded version itself is not FDA-approved.
Why is tirzepatide compounded?
Compounding can sometimes be used when a patient’s specific medical needs cannot be met by an FDA-approved medication—for example, when a patient needs a particular formulation or has an ingredient-related need. FDA says compounded drugs should generally be used when an FDA-approved option cannot meet the patient’s medical needs.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No. Compounded tirzepatide should not be described as a generic version of Zepbound or Mounjaro. FDA-approved drugs undergo FDA review for safety, effectiveness and quality before marketing, whereas compounded drugs do not undergo that premarket FDA review.
What are the concerns?
FDA has reported concerns involving compounded GLP-1 products, including dosing errors, product-quality issues, contamination risks and adverse events. As of May 31, 2026, FDA had received more than 730 reports of adverse events associated with compounded tirzepatide, although the agency notes that it is not always possible to determine whether the drug directly caused a reported event.
Because compounded products can have different concentrations or instructions, patients should follow the exact dosing instructions provided by their healthcare professional and compounding pharmacy rather than converting doses themselves.
In simple terms: Compounded tirzepatide is a pharmacy-prepared version of tirzepatide made for specific circumstances. It is not the same regulatory product as FDA-approved tirzepatide medicines, and patients should discuss its appropriateness and sourcing with a qualified healthcare professional.
